Frovatriptan 2.5mg plus dexketoprofen (25mg or 37.5 mg) in menstrually related migraine. Subanalysis from a double-blind, randomized trial

G. Allais, G. Bussone, V. Tullo, P. Cortelli, F. Valguarnera, P. Barbanti, G. Sette, F. D'Onofrio, M. Curone, C. Benedetto

Research output: Contribution to journalArticle


Purpose: The purpose of this article is to investigate the efficacy and safety of frovatriptan plus dexketoprofen 25 or 37.5 mg (FroDex25 or FroDex37.5, respectively) compared to that of frovatriptan 2.5 mg (Frova) in menstrually related migraine (MRM). Aim: The aim of this article is to analyze a subgroup of 76 women who treated an MRM attack in this multicenter, randomized, double-blind, parallel-group study. Methods: The primary end-point was the proportion of patients who were pain free (PF) at two hours. Secondary endpoints included pain-relief (PR) at two hours and 48 hours sustained pain free (SPF). Results: PF rates at two hours were 29% under Frova, 48% under FroDex25 and 64% under FroDex37.5 (p

Original languageEnglish
Pages (from-to)45-50
Number of pages6
Issue number1
Publication statusPublished - 2015



  • Dexketoprofen
  • Frovatriptan
  • Menstrually related migraine
  • Migraine attacks

ASJC Scopus subject areas

  • Clinical Neurology

Cite this